Open Outbreak

Hantavirus infection

Also known as: hantavirus, HPS, HFRS, hantavirus pulmonary syndrome, hantavirus cardiopulmonary syndrome, HCPS, hemorrhagic fever with renal syndrome, Orthohantavirus

Hantavirus infection is a group of viral illnesses usually acquired from infected rodents. People can become infected through exposure to rodent urine, droppings or saliva, including breathing in contaminated particles. Exposure can occur when cleaning rodent-infested buildings or spending time in forests, fields and farms. Different hantaviruses cause different illnesses. Hantavirus pulmonary syndrome mainly affects the lungs and can progress to severe breathing problems and shock. Hemorrhagic fever with renal syndrome affects the kidneys and can also cause bleeding. Both can be serious. Most transmission is from rodents to people. Andes virus is an important exception: limited person-to-person spread has occurred after close, prolonged contact. A 2026 review reports that specific treatments and licensed vaccines are not widely available. Hospital assessment and care are important when severe illness develops. The latest WHO update retrieved for this page, dated 2026-07-02, described the Andes virus outbreak linked to the M/V Hondius cruise ship as contained, with no further related transmission expected.

Key facts

TransmissionPrimarily exposure to infected rodent urine, droppings or saliva, including inhalation of contaminated particles and contact with contaminated surfaces. Limited person-to-person transmission is documented for Andes virus, generally after close, prolonged exposure.
Incubationunknown; the retrieved literature and WHO excerpts do not establish an incubation range. WHO used a 42-day contact follow-up period for the 2026 cruise-ship outbreak.
Case fatalityA 2008 treatment review reported approximately 40% mortality for HPS across the Americas. WHO reported 13 cases and three deaths, a case fatality ratio of 23%, in the cruise-ship outbreak as of 2026-07-02. HFRS fatality and separate treated versus untreated estimates are unknown from the retrieved sources.
Reproduction numberunknown
VaccineA 2026 systematic review reports that licensed vaccines are not widely available; the retrieved excerpt does not specify country-level availability.
TreatmentSpecific therapeutics are not widely available according to a 2026 systematic review. WHO describes hospital care, intensive care and medical evacuation during severe outbreaks; the retrieved sources do not establish a proven specific antiviral regimen.
ReservoirRodents maintain persistent infections and are the main source of human exposure. Reservoir species differ between hantaviruses.
Endemic regionsHFRS occurs in Asia and Europe; HPS occurs in the Americas. Andes virus remains endemic in South America.

Transmission

Most human infections begin with exposure to infected rodents, rather than another person. Virus-containing urine, droppings or saliva can contaminate the environment. Breathing in contaminated particles is a recognized route of infection. WHO also describes exposure through contaminated surfaces. Cleaning rodent-infested buildings is one setting where exposure can occur; forests, fields and farms are others. Andes virus is an important exception to the usual rodent-to-human pattern. It can spread between people, generally through close and prolonged exposure. In the 2026 cruise-ship outbreak, WHO considered initial infections likely to have been acquired on land, followed by person-to-person transmission aboard the vessel. The exact initial source remained undetermined.

Symptoms and severity

Hantavirus infection can cause two main syndromes. Hantavirus pulmonary syndrome can begin with fever, tiredness and muscle pain, followed by cough and shortness of breath. Severe illness can progress to respiratory failure and shock. Hemorrhagic fever with renal syndrome can cause fever, headache, abdominal pain, nausea, bleeding and kidney failure. Severity varies with the virus and the outbreak. A 2008 review reported approximately 40% mortality for HPS across the Americas. In the 2026 cruise-ship outbreak, WHO reported three deaths among 13 cases as of 2026-07-02, a case fatality ratio of 23%. That small outbreak estimate should not be treated as a universal risk for every hantavirus infection.

Treatment and vaccines

The retrieved evidence does not identify a widely available specific treatment or vaccine. A 2026 systematic review explicitly describes the absence of widely available specific therapeutics or licensed vaccines. This does not establish that vaccines are unavailable in every country; the excerpt provides no country-by-country details. Severe illness may require hospital or intensive care. WHO's response to the 2026 cruise-ship outbreak included clinical care, medical evacuation, laboratory testing and isolation of cases. As of 2026-07-02, eight hospitalized cases had recovered and been discharged, while two remained under treatment. The retrieved material does not support a comparison of survival with and without treatment, or a recommendation for a particular antiviral drug.

Where it occurs

Hantaviruses occur in different regions because different viruses are maintained by different animal hosts. The kidney-affecting syndrome, HFRS, occurs in Asia and Europe. The lung-affecting syndrome, HPS, occurs in the Americas. WHO describes Andes virus as remaining endemic in South America, meaning it continues to occur there. Human exposure is often reported in rural settings, including forests, fields and farms, but rodent-infested buildings can also provide opportunities for infection. Travel-associated cases can be diagnosed far from the place where exposure happened. The international distribution of cases in the 2026 cruise-ship outbreak therefore does not, by itself, show that local rodent-to-human transmission became established in each affected country.

Recent history

Open Outbreak's supplied archive contains seven hantavirus events, spanning 1996 through 2026. Entries cover Bosnia and Herzegovina, the Americas, Panama, Yosemite National Park, Argentina and the multinational cruise-ship outbreak. These are selected archived events, not a count of all infections or outbreaks worldwide. WHO published five notices about the 2026 M/V Hondius outbreak. Its latest retrieved update, dated 2026-07-02, reported 13 cases, including 12 laboratory-confirmed cases and one probable case, and three deaths. All identified contacts had completed the 42-day follow-up period without additional secondary cases being detected. WHO described transmission as interrupted and the outbreak as contained. No later WHO update was retrieved for this page, prepared for 2026-11-15.

What to watch

Important warning signals would include locally acquired cases in new regions, rising exposure to infected rodents, or linked infections that suggest more extensive person-to-person spread. For Andes virus, transmission beyond the close, prolonged contact described by WHO would deserve particular investigation. Diagnostic delays also matter: during the 2026 outbreak, limited testing capacity on a remote island delayed confirmation until a sample could be tested elsewhere. Access to hospital care, contact follow-up and laboratory testing should be monitored alongside case numbers. Because specific treatments and vaccines are not widely available, any new evidence of effective protection and its supply would be important. The retrieved sources do not identify a treatment-resistance problem; resistance should not be presented as an established current threat.

Updated